• Home
• About GAMMAGARD Therapy
  • Tolerability
  • Efficacy
  • Convenience
  • Viral Safety
  • Dosage & Administration
  • Clinical Questions
• Help for Patients
• Professional Resources
  • Contact Medical Information
  • Order Tools & Resources
  • GARDian Program
  • Professional Links
• Ordering & Reimbursement
  • Order GAMMAGARD LIQUID Therapy
  • Reimbursement Hotline

GARD Your Patients

About GAMMAGARD LIQUID Therapy

GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10% therapy is the most widely used 10% IVIG.^1*

• Tolerability

  GAMMAGARD LIQUID therapy is formulated to address a wide range of patient needs. With no added sugars, no added sodium, no added preservatives, and no latex in the packaging, GAMMAGARD LIQUID therapy helps promote a better infusion experience.²

• Efficacy

  For consistent therapy from infusion to infusion, consider GAMMAGARD LIQUID therapy. A pivotal open label study has demonstrated the efficacy of GAMMAGARD LIQUID therapy with zero validated acute serious bacterial infections and median IgG trough levels maintained at 960 to 1,120 mg/dL.^2,3

• Convenience

  GAMMAGARD LIQUID therapy provides efficiency and ease of use. Learn about the convenience features that distinguish GAMMAGARD LIQUID therapy, including 5 color-coded sizes, 9-month storage at room temperature,^2** and peel-off labels.

• Viral Safety

  With GAMMAGARD LIQUID therapy, you can give your patients confidence in their therapy. GAMMAGARD LIQUID therapy is sourced and processed exclusively from plasma collected at FDA-registered donor sites, then treated with a dedicated 3-step viral inactivation/removal process.²

* Based on the number of grams distributed in the U.S. Jan-Dec 2008.

** Within 24 months of manufacture

Please see the detailed Important Risk Information and Full Prescribing Information for GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] for full prescribing details.

1. The Marketing Research Bureau. The Plasma Fractions Market in the United States 2008. Orange, CT: Marketing Research Bureau ; 2009.
2. GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10% package insert. Westlake Village, CA. Baxter International Inc.; October 2009.
3. Church JA, Leibl H, Stein MR, et al, and the US-PID-IGIV 10% Study Group. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. Journal of Clinical Immunology. 2006;26:388-395.